ABL advancing HIV vaccine as part of 7 year, $318m contract

By Melissa Fassbender contact

- Last updated on GMT

ABL provides contract manufacturing and laboratory research services. (Image: iStock/Aunt_Spray)
ABL provides contract manufacturing and laboratory research services. (Image: iStock/Aunt_Spray)
ABL, Inc. has been awarded a preclinical development support contract to help advance an HIV vaccine and other biologics candidates.

According to the global contract research and manufacturing service provider, the goal of the contract is to accelerate promising HIV prophylactic modalities into the clinic.

The Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) awarded the contract, which spans seven years with a maximum funding level of $318m.

Per the contract, ABL will provide various services including product development planning, process and bioanalytical assay development, cGMP manufacturing, product safety and release testing, as well as immunogenicity testing, and regulatory support.

Rebecca K. Harston, Ph.D., associate director of marketing at ABL told us the company has been building capacity steadily since moving into its purpose-built facility in 2011.

The contract in question is an indefinite delivery/indefinite quantity (ID/IQ) contract, so the number and complexity of task orders or projects are unknown at this time. However, Harston said, "ABL has several of these contracts and is adept in adjusting resources (equipment, facility, personnel) as required to answer customer requirements​."

Most work will be performed in ABL’s manufacturing and laboratory space at its Rockville, MD headquarters. 

Government contracts

Earlier this year ABL was also awarded​ an ID/IQ contract by the Biomedical Advanced Research and Development Authority (BARDA).

As part of the contract – work up to $50m over five years – the company is providing fill/finish services for live virus-based medical countermeasures (MCM).

The work is being carried out at ABL’s GMP facilities in Rockville, MD and Strasbourg, France.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers